A Revolutionary Approach to Cancer Treatment


Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial.


Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

November 13, 2018
Jounce Therapeutics Reports Third Quarter 2018 Financial Results

November 6, 2018
Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018

October 1, 2018
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Cary Pfeffer, M.D.
Partner

Robert Kamen, Ph.D.
Venture Partner